September 19, 2020

The Niche

Knoepfler lab stem cell blog

Prochymal

4 min read

What’s the deal with lung stem cells and stem cells for lungs? For a long time researchers found that stem cells were elusive in adult lungs. There was debate about whether they even existed, but it now seems fairly established that there are some of the little guys in there. Just because one of the early papers on purported human lung stem cells came from Piero Anversa and has been retracted doesn’t mean these stem cell cells don’t exist at all. Other groups have reported …Read More

6 min read

Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem cell-related trials such as Prochymal so I’m interested to learn more about how this product and this trial are unique. Can you fill me in? In many ways, our trial …Read More

4 min read

We hear so much about exciting potential stem cell therapies, but what about stem cell treatment cost? Some of these “therapies” are rigorously evaluated ones in the FDA clinical trial pipeline and others are available right now mainly through predatory stem cell clinics. Earlier this year I posted about the cost of the offerings of dubious stem cell clinics. In this post, I address the cost of a future, legitimate, FDA-approved stem cell therapy. How high will that be? (2020 update: See this polling …Read More

2 min read

The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, reportedly worth up to $100 million if specific milestones are reached in clinical trials in the future, will boost Mesoblast’s leadership in MSC-related clinical applications, although Mesoblast, led by …Read More